Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatitis D

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    381 result(s) found for: Hepatitis D. Displaying page 3 of 20.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-016357-17 Sponsor Protocol Number: AI463-189 Start Date*: 2010-12-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive Revised Pro...
    Medical condition: CHRONIC HEPATITIS B VIRUS,PEDIATRIC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) GR (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003754-84 Sponsor Protocol Number: M13-774 Start Date*: 2013-04-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe...
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003665-35 Sponsor Protocol Number: EIG-LMD-002 Start Date*: 2022-06-10
    Sponsor Name:Eiger BioPharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic He...
    Medical condition: Chronic Hepatitis Delta Virus (HDV) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10019762 Hepatitis D PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001081-42 Sponsor Protocol Number: HepNet-aHCV-IV Start Date*: 2014-10-21
    Sponsor Name:Hannover Medical School
    Full Title: Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study
    Medical condition: Adults with acute genotype 1 hepatitis C virus (HCV) infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    18.1 10021881 - Infections and infestations 10065051 Acute hepatitis C PT
    18.1 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015121-37 Sponsor Protocol Number: ANRS HC 23 Start Date*: 2009-12-10
    Sponsor Name:ANRS
    Full Title: Etude multicentrique randomisée ouverte comparant la réduction virale et la tolérance de l’association IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez des patients atteints d...
    Medical condition: Evaluation de l’activité antivirale d’injections hebdomadaires d’un nouvel interféron α-2b à libération prolongée formulé avec Medusa® (IFNα-2bXL) chez des patients atteints d’hépatite chronique v...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010149-29 Sponsor Protocol Number: AI444-014 Start Date*: 2009-05-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2a Study of BMS-790052 in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects with Chronic Hepatitis C Virus Genotype 1 Infection
    Medical condition: Chronic Hepatitis C Virus Genotype 1 Infection in Treatment Naïve Subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018295-24 Sponsor Protocol Number: AI444-010 Start Date*: 2010-07-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection Revised Protocol Number ...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003535-27 Sponsor Protocol Number: 1241.36 Start Date*: 2012-10-17
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) GB (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001033-39 Sponsor Protocol Number: VIR-2218-1006 Start Date*: 2022-08-30
    Sponsor Name:Vir Biotechnology, Inc.
    Full Title: A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection
    Medical condition: Chronic HBV infection.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003167-54 Sponsor Protocol Number: EIG-LNF-011 Start Date*: 2019-06-24
    Sponsor Name:Eiger BioPharmaceuticals, Inc.
    Full Title: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared...
    Medical condition: The proposed indication for lonafarnib coadministered with ritonavir is for the treatment of chronic HDV infection. Approximately 5% of HBV-infected individuals are infected with HDV worldwide. Ch...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019763 Hepatitis delta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) BG (Completed) GR (Completed) ES (Ongoing) SE (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004993-15 Sponsor Protocol Number: MV21371 Start Date*: 2008-03-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Vi...
    Medical condition: Chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022867-37 Sponsor Protocol Number: CDEB025A2301 Start Date*: 2011-05-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with peg-IFN alfa2a and ribavirin in hepatitis C genotype 1 treatment-naïve pati...
    Medical condition: Chronic Hepatitis C genotype 1 treatment-naïve patients
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002385-49 Sponsor Protocol Number: IN-UK-311-3956 Start Date*: 2017-11-27
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: IN-UK-311-3956: A Feasibility Study of the Switch of Tenofovir disoproxil fumarate to Tenofovir alafenamide fumarate and the Effect on Glomerular Function in Chronic Hepatitis B and HIV co-infected...
    Medical condition: HIV and Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    20.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-003567-10 Sponsor Protocol Number: 217023 Start Date*: 2021-12-23
    Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS
    Full Title: A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonuc...
    Medical condition: Hepatitis B virus (HBV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005499-46 Sponsor Protocol Number: Heparc-2008 Start Date*: 2016-06-24
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination with Other Therapeutics in Patients with Chronic Hepatitis B Virus (HBV) Infection (MONARCH)
    Medical condition: Chronic Hepatitis B Virus (HBV) Infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004544-30 Sponsor Protocol Number: 1241.37 Start Date*: 2013-04-03
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pe...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Prematurely Ended) NO (Completed) IT (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) DE (Completed) DK (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-004605-34 Sponsor Protocol Number: Debio 025-HCV-205 Start Date*: Information not available in EudraCT
    Sponsor Name:Debiopharm S.A.
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic ...
    Medical condition: chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    11.0 10008912 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006225-14 Sponsor Protocol Number: ANRS HC 22 Start Date*: 2009-06-18
    Sponsor Name:ANRS
    Full Title: Essai clinique multicentrique, randomisé et contrôlé comparant l’efficacité de la pioglitazone versus placebo chez les patients avec hépatite virale chronique C de génotype non-2, non-3, insulinoré...
    Medical condition: Chronic hepatitis C Insulin resistance
    Disease: Version SOC Term Classification Code Term Level
    11.1 10008912 LLT
    11.1 10022489 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-021490-37 Sponsor Protocol Number: V419-007 Start Date*: 2011-03-09
    Sponsor Name:Sanofi Pasteur MSD
    Full Title: A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months.
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    14.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003533-41 Sponsor Protocol Number: 1241.20 Start Date*: 2012-12-04
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec...
    Medical condition: Chronic infection with HCV - genotype 1
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) GB (Completed) ES (Completed) IE (Completed) IT (Completed) NL (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 00:52:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA